A Phase 1, Randomized, Controlled, Observer-blinded Trial To Evaluate The Safety And Immunogenicity Of A Multivalent Pneumococcal Conjugate Vaccine In Healthy Adults Aged 18 To 49 Years
Phase of Trial: Phase I
Latest Information Update: 28 Sep 2017
At a glance
- Drugs Pneumococcal vaccine conjugate (Primary) ; DTaP vaccine
- Indications Pneumococcal infections
- Focus Adverse reactions; First in man
- Sponsors Pfizer
- 21 Sep 2017 Status changed from active, no longer recruiting to completed.
- 16 Feb 2017 Planned End Date changed from 1 Sep 2017 to 1 Aug 2017.
- 16 Feb 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Aug 2017.